• Oncoceutics, Inc. and its commercial and academic collaborators will be presenting multiple abstracts at the 2019 annual meeting of the American Association for Cancer Research in Atlanta, Georgia, on March 29th to April 3rd.  These abstracts will highlight ONC201’s unique mechanism of action, various single agent and combination data, and characterization of other imipridones, including ONC206.

    The list of abstracts, along with the time and location of their presentation, can be found below:

    Abstract

     

    Date

     

    Location

     

    ONC201

     

       
    1286 / 1 – ONC201 inhibits RET and IGFBP2 signaling through ATF4 mediated- Integrated stress response in medullary thyroid cancer

     

     April 1, 2019, 8:00 AM – 12:00 PM Section 14
    249 / 12 – Combination of ONC201 with radiation exhibits synergistic efficacy in high grade gliomas and other advanced cancers

     

     March 31, 2019, 1:00 PM – 5:00 PM Section 10
    5183 / 1 – ONC201 induces acetylation of histone binding within the p21 (CDKN1A) gene promoter

     

     April 3, 2019, 8:00 AM – 12:00 PM Section 35
    2664 / 18 – Differential activation of the integrated stress response correlates with anti-tumor activity of imipridones ONC201 and ONC206 in pediatric sarcomas

     

     April 1, 2019, 1:00 PM – 5:00 PM Section 39
    4808 / 22 – Preclinical studies of the combination of ONC201, radiotherapy and Temozolomide against GBM, DIPG and ATRT cell lines

     

     April 3, 2019, 8:00 AM – 12:00 PM Section 13
    2928 / 16 – New insight into signaling contexts for the administration of the imipridone ONC201 to prostate cancer cells

     

     April 2, 2019, 8:00 AM – 12:00 PM Section 8
    364 / 25 – The dopamine receptor D2 antagonist ONC201 has anti-tumorigenic activity in obesity-driven epithelial ovarian cancer

     

     March 31, 2019, 1:00 PM – 5:00 PM Section 14
    258 / 2 – Recombinant human TRAIL or a DR5 agonistic antibody convert the response of non-triple negative breast cancer cells to ONC201 from anti-proliferative to apoptotic

     

    March 31, 2019, 1:00 PM – 5:00 PM Section 11
    262 / 6 – Anti-tumorigenic effect of ONC201 is enhanced by combination treatment with TRAIL or a DR5 agonist in endometrial cancer in vitro

     

     March 31, 2019, 1:00 PM – 5:00 PM Section 11
    Neuro-Tumor Club – Selective targeting of dopamine receptor dysregulation in high grade gliomas with imipridone ONC201

     

    April 1, 2019, 5:00 PM – 9:00 PM Emory University School of Medicine James B. Williams Medical Education Building
    Imipridone GPCR SAR

     

       
    2749 / 1 – Defining structure activity relationships for GPCR engagement and anti-cancer efficacy of imipridone small molecules

     

     April 2, 2019, 8:00 AM – 12:00 PM Section 1
    ONC206

     

       
    3877 / 27 – IND-enabling characterization of DRD2/3 imipridone antagonist ONC206 for oncology

     

     April 2, 2019, 1:00 PM – 5:00 PM Section 12
    Oral Talks

     

       
    2720 – Mitochondrial ClpP-mediated proteolysis induces selective cancer cell lethality

     

     April 1, 2019, 4:35 PM – 4:50 PM  Room A313 – Georgia World CC
    Neuro-Tumor Club – IND-enabling characterization of DRD2/3 imipridone antagonist ONC206 for oncology

     

    April 1, 2019, 8:20 PM – 9:30 PM Emory University School of Medicine James B. Williams Medical Education Building

     

Photostream